Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Needed Simple Pragmatic COVID-19 Trial For Repurposing Candidates, Woodcock Says

Executive Summary

One such trial is being developed, but was needed early in the pandemic to answer many lingering questions about potential COVID-19 treatments.

You may also be interested in...



Would Biden’s ‘Advanced Research’ Projects Mesh Well At NIH?

HHS Secretary Becerra answers questions about the scope of the proposed ARPA-H agency; more to come during NIH budget hearing.

Abernethy’s Departure From US FDA Gives Next Commissioner Options For A New Number Two

Janet Woodcock has been in the lead in the commissioner race for months without an announcement, but now serious doubts are being cast on her candidacy, including the tone of remarks at a White House press briefing.

EMA Turns Down Ivermectin As COVID-19 Treatment

The EU medicines regulator found that results from clinical studies with ivermectin to treat COVID-19 were varied and inconclusive.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel